A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest.
Abstract
Cellular responses to stimuli can evolve over time, resulting in distinct early and
late phases in response to a single signal. DNA damage induces a complex response
that is largely orchestrated by the transcription factor p53, whose dynamics influence
whether a damaged cell will arrest and repair the damage or will initiate cell death.
How p53 responses and cellular outcomes evolve in the presence of continuous DNA damage
remains unknown. Here, we have found that a subset of cells switches from oscillating
to sustained p53 dynamics several days after undergoing damage. The switch results
from cell cycle progression in the presence of damaged DNA, which activates the caspase-2-PIDDosome,
a complex that stabilizes p53 by inactivating its negative regulator MDM2. This work
defines a molecular pathway that is activated if the canonical checkpoints fail to
halt mitosis in the presence of damaged DNA.
Type
Journal articleSubject
HumansUltraviolet Rays
Mitosis
Models, Biological
Tumor Suppressor Protein p53
Proto-Oncogene Proteins c-mdm2
Caspase 2
Death Domain Receptor Signaling Adaptor Proteins
DNA Breaks, Double-Stranded
Proteolysis
Cell Cycle Checkpoints
MCF-7 Cells
A549 Cells
Permalink
https://hdl.handle.net/10161/25566Published Version (Please cite this version)
10.1016/j.celrep.2020.107995Publication Info
Tsabar, Michael; Mock, Caroline S; Venkatachalam, Veena; Reyes, Jose; Karhohs, Kyle
W; Oliver, Trudy G; ... Lahav, Galit (2020). A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest.
Cell reports, 32(5). pp. 107995. 10.1016/j.celrep.2020.107995. Retrieved from https://hdl.handle.net/10161/25566.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Trudy G Oliver
Professor of Pharmacology and Cancer Biology
The Oliver Lab is focused on understanding the biology of under-studied subtypes of
lung cancer, specifically squamous and small cell lung cancer (SCLC). We investigate
mechanisms of tumor initiation, progression, plasticity, and drug resistance to uncover
vulnerabilities that can be therapeutically targeted. We capitalize on state-of-the-art
mouse and patient-derived models to identify and test novel treatment strategies,
with the goal of translating these findings to the clinic.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info